-39.1%
JOBY vs MRNA
+85.2%
-124.3%
-79.7%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +1.3% | +5.4% | -4.1% | +0.8% |
| 7D | -5.2% | -1.1% | -4.1% | -5.1% |
| 30D | -19.7% | +126.1% | -145.8% | -32.2% |
| 3M | -31.7% | +190.0% | -221.8% | -45.5% |
| 6M | -37.5% | +157.2% | -194.8% | -49.0% |
| YTD | -51.6% | +388.2% | -439.8% | -65.4% |
| 1Y | -53.3% | +467.0% | -520.3% | -67.8% |
| 3Y | -12.2% | +36.1% | -48.3% | -26.4% |
| 5Y | -31.3% | -68.0% | +36.7% | -42.1% |
| All | -39.1% | +85.2% | -124.3% | -51.2% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling